Design, Synthesis, and Bioactivation of O-Glycosylated Prodrugs of the Natural Nitric Oxide Precursor Nω-Hydroxy-l-arginine
Abstract
Naturally occurring Nω-hydroxy-l-arginine (NOHA, 1) is the best substrate of NO synthases (NOS). The development of stable and bioavailable prodrugs would provide a pharmacologically valuable strategy for the treatment of cardiovascular diseases that are associated with endothelial dysfunction. To improve NOHAs druglike properties, we demonstrate that O-substitution by (glycosylic) acetal formation greatly increased the chemical stability of the hydroxyguanidine moiety and provided a nontoxic group that could be easily bioactivated by glycosidases. A straightforward synthetic concept was devised and afforded a series of diversely substituted prodrugs by O-conjugation of the hydroxyguanidine moiety with different monosaccharides. Systematic exploration of their bioactivation profile revealed that glucose-based prodrugs were more efficiently bioactivated than their galactose counterparts. NOS-dependent cytosolic NO release was quantified by automated fluorescence microscopy in a cell-based assay with murine macrophages. Glucose-based prodrugs performed particularly well and delivered cellular NO levels comparable to 1, demonstrating proof-of-concept.
Cited By
This article is cited by 7 publications.
- Weijun Wu, Ruilin Guan, Xinxing Liao, Xu Yan, Thomas W. Rees, Liangnian Ji, Hui Chao. Bimodal Visualization of Endogenous Nitric Oxide in Lysosomes with a Two-Photon Iridium(III) Phosphorescent Probe. Analytical Chemistry 2019, 91 (15) , 10266-10272. https://doi.org/10.1021/acs.analchem.9b02415
- Jason Muller, Luca Marchisio, Rym Attia, Andy Zedet, Robin Maradan, Maxence Vallet, Alison Aebischer, Dominique Harakat, François Senejoux, Christophe Ramseyer, Sarah Foley, Bruno Cardey, Corine Girard, Marc Pudlo. A colorimetric assay adapted to fragment screening revealing aurones and chalcones as new arginase inhibitors. RSC Medicinal Chemistry 2024, 15 (5) , 1722-1730. https://doi.org/10.1039/D3MD00713H
- Swanand Kulkarni, Dyuti Bhandary, Yogesh Singh, Vikramdeep Monga, Suresh Thareja. Boron in cancer therapeutics: An overview. Pharmacology & Therapeutics 2023, 251 , 108548. https://doi.org/10.1016/j.pharmthera.2023.108548
- Jason Muller, Rym Attia, Andy Zedet, Corine Girard, Marc Pudlo. An Update on Arginase Inhibitors and Inhibitory Assays. Mini-Reviews in Medicinal Chemistry 2022, 22 (15) , 1963-1976. https://doi.org/10.2174/1389557522666211229105703
- Seongmin Park, Yelim Yi, Mi Hee Lim. Reactivity of Flavonoids Containing a Catechol or Pyrogallol Moiety with Metal‐Free and Metal‐Associated Amyloid‐β. Bulletin of the Korean Chemical Society 2021, 42 (1) , 17-24. https://doi.org/10.1002/bkcs.12172
- Johnny Moretto, Marc Pudlo, Céline Demougeot. Human-based evidence for the therapeutic potential of arginase inhibitors in cardiovascular diseases. Drug Discovery Today 2021, 26 (1) , 138-147. https://doi.org/10.1016/j.drudis.2020.11.005
- Bartlomiej Borek, Tadeusz Gajda, Adam Golebiowski, Roman Blaszczyk. Boronic acid-based arginase inhibitors in cancer immunotherapy. Bioorganic & Medicinal Chemistry 2020, 28 (18) , 115658. https://doi.org/10.1016/j.bmc.2020.115658